Pfizer Polska sp. z o.o.

Advertising agencies

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2001-06-26
Share capital
33,860,000.00 PLN
Activity description

Pfizer Polska focuses on vaccines and the development of oncology therapies for frequently occurring and difficult-to-treat cancers. The company traces its origins to a chemical enterprise founded in New York in the mid-19th century by Charles Pfizer and Charles Erhardt.

Registered address
ul. Żwirki I Wigury 16B, 02-092 Warszawa, Poland
Website
Phone
Social media
Electronic delivery address
AE:PL-18407-72430-EAUTT-18

Financials

Revenue history (in m)

From the notes

Current income tax (CIT due)$870,668

Filing timeliness

Financial statements were filed on time, on average 42 days early. All were audited by a statutory auditor.

  • 202526/05/2026
  • 202429/05/2025
  • 202320/05/2024
  • 202226/04/2023
  • 202119/05/2022
  • 202024/05/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Industry · Advertising agencies6 / 3,958
Top <1%
City · Warszawa588 / 56,729
Top 1.0%
Voivodeship · Mazowieckie749 / 76,892
Top <1%
Country · Poland2,071 / 297,069
Top <1%

Results vs industry

Revenue
This companyUSD 110.63mMedianUSD 115.83kAverageUSD 1.12m
Net profit
This companyUSD 4.42mMedianUSD 4.00kAverageUSD 75.38k
Operating costs
This companyUSD 104.15mMedianUSD 100.95kAverageUSD 1.02m
Assets
This companyUSD 98.42mMedianUSD 57.45kAverageUSD 671.79k

Offer

Websites

The company has 6 websites.

  • pfizer.plStrona główna | Pfizer | Polska
    LinkedIn AdsCloudflare
  • kleszcze.info.plWszystko o kleszczach, chorobach odkleszczowych i szczepieniach
    LinkedIn AdsCloudflare
  • pfizerpro.plStrona główna | PfizerPro
    LinkedIn AdsCloudflare

Public procurement

2 tenders recorded as contractor: 1 national ($84,860) and 1 EU ($234,699).

SubjectAmount
Supply of medicinal products from drug programmes and various medicinal products
$234.7K
Supply of medicinal products – lorlatinibum, dacomitinibum
$84,860

Trademarks

The company currently holds no active trademarks with the Polish Patent Office. 1 mark has expired or was not registered. The first mark was filed in 2003.

MarkNumberClassesStatusProtected until
DLA ZDECYDOWANYCH NA RZUCENIE PALENIA (word)Z.2680495, 10, 30Proceedings discontinued –
MarkProtected until
DLA ZDECYDOWANYCH NA RZUCENIE PALENIA (word)–

Authorized Representatives

Dorota Anna Hryniewiecka-Firlej age 62 – President of the Management Board

Manner of representation

The President of the Management Board is authorized to submit declarations and sign on behalf of the company independently, whereas, in the case of a multi-member management board, the President of the Management Board independently, or two other members of the management board acting jointly, or a member of the management board acting jointly with a commercial proxy are authorized to do so.

Ownership

OwnerSharesShare valueStake
Pfizer Luxembourg Sarl
33,860$9,146,407.35100%

Beneficial owners

Person

Capital group

The company belongs to the Pfizer Inc. (United States) group. Its direct owner is Pfizer Luxembourg S.à r.l (Luxembourg). The group has 149 companies, 146 of them abroad.

NameCountry
Pfizer Trading PolskaPoland
"Pfizer Corporation Austria" Gesellschaft M.B.H.Austria
AHP Holdings BVNetherlands
AHP Manufacturing B.V.Netherlands
C.P. Pharmaceuticals International C.V.Netherlands

Bank accounts

Registered as a VAT taxpayer on 2003-11-30.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 300.6K

MSiG notices

10 notices recorded in the Court and Commercial Gazette (MSiG).

Publication dateEvent
Aug 11, 2020Return of additional payments
Aug 31, 2016Commercial Companies Code notice
Jul 21, 2014Commercial Companies Code notice
Oct 2, 2013Commercial Companies Code notice
Feb 24, 2012Call to creditors

Public aid

No public aid cases recorded in the last 10 years.

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Novartis Poland sp. z o.o.
MSD Polska Dystrybucja sp. z o.o.
Bristol-Myers Squibb Polska sp. z o.o.
Astellas Pharma sp. z o.o.
Accord Healthcare Polska sp. z o.o.
Gilead Sciences Poland sp. z o.o.
Amgen sp. z o.o.
Ipsen Poland sp. z o.o.
Magnapharm Poland sp. z o.o.
Pierre Fabre Medicament Polska . sp. z o.o.

Change history

DateEvent
2026-11-09PKD change
2018-09-13Address change
2012-08-03Share capital reduction
2011-03-28Share capital increase
2010-10-29Address change

FAQ

Last updated: 2026-11-09